Literature DB >> 18940257

Cytokine related therapies for autoimmune disease.

Terry B Strom1, Maria Koulmanda.   

Abstract

In short, manipulation of cytokine pathways shows promise as a mean to tilt the balance of immunity toward tolerance. Effective and regulatory T cells vary in their response to a variety of cytokines. In particular, the ability of certain cytokines, for example, IL-2, to provide vital survival signals to regulatory cells and to trigger death of effector T cells or impede IL-15 driven expansion of memory cells has spurred several trials. The ability of IFNgamma, IL-4, TNFalpha, and lymphotoxin to exert selective effects upon crucial lymphocyte subset populations in vivo may also enable translation into potent therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18940257      PMCID: PMC3747560          DOI: 10.1016/j.coi.2008.10.003

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  48 in total

Review 1.  The molecular basis of T helper 1 and T helper 2 cell differentiation.

Authors:  A O'Garra; N Arai
Journal:  Trends Cell Biol       Date:  2000-12       Impact factor: 20.808

2.  Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.

Authors:  Y Li; X C Li; X X Zheng; A D Wells; L A Turka; T B Strom
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

Review 3.  Homeostasis of alpha beta TCR+ T cells.

Authors:  P Marrack; J Bender; D Hildeman; M Jordan; T Mitchell; M Murakami; A Sakamoto; B C Schaefer; B Swanson; J Kappler
Journal:  Nat Immunol       Date:  2000-08       Impact factor: 25.606

Review 4.  Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.

Authors:  T A Waldmann; S Dubois; Y Tagaya
Journal:  Immunity       Date:  2001-02       Impact factor: 31.745

5.  Normal lymphoid homeostasis and lack of lethal autoimmunity in mice containing mature T cells with severely impaired IL-2 receptors.

Authors:  T R Malek; B O Porter; E K Codias; P Scibelli; A Yu
Journal:  J Immunol       Date:  2000-03-15       Impact factor: 5.422

6.  Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice.

Authors:  D G Alleva; R P Pavlovich; C Grant; S B Kaser; D I Beller
Journal:  Diabetes       Date:  2000-07       Impact factor: 9.461

7.  Control of homeostasis of CD8+ memory T cells by opposing cytokines.

Authors:  C C Ku; M Murakami; A Sakamoto; J Kappler; P Marrack
Journal:  Science       Date:  2000-04-28       Impact factor: 47.728

8.  Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor.

Authors:  Q Wu; B Salomon; M Chen; Y Wang; L M Hoffman; J A Bluestone; Y X Fu
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

9.  Certified professionals: CD4(+)CD25(+) suppressor T cells.

Authors:  E M Shevach
Journal:  J Exp Med       Date:  2001-06-04       Impact factor: 14.307

10.  Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.

Authors:  Ruka Setoguchi; Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  8 in total

Review 1.  Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Authors:  Jeffrey A Bluestone; Kevan Herold; George Eisenbarth
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

2.  Pathogenic T cells have a paradoxical protective effect in murine autoimmune diabetes by boosting Tregs.

Authors:  Yenkel Grinberg-Bleyer; David Saadoun; Audrey Baeyens; Fabienne Billiard; Jérémie D Goldstein; Sylvie Grégoire; Gaëlle H Martin; Rima Elhage; Nicolas Derian; Wassila Carpentier; Gilles Marodon; David Klatzmann; Eliane Piaggio; Benoît L Salomon
Journal:  J Clin Invest       Date:  2010-11-22       Impact factor: 14.808

Review 3.  2011 Update: antigen-specific therapy in type 1 diabetes.

Authors:  Aaron W Michels; Matthias von Herrath
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-08       Impact factor: 3.243

4.  Molecular characterization and functional activity of an IL-15 antagonist MutIL-15/Fc human fusion protein.

Authors:  Xiaoyi Yang; Abraham Kallarakal; Nirmala Saptharishi; Hengguang Jiang; Zhiwen Yang; Yueqing Xie; George Mitra; Xin Xiao Zheng; Terry B Strom; Gopalan Soman
Journal:  Mol Pharm       Date:  2013-01-22       Impact factor: 4.939

5.  New Approaches to the Immunotherapy of Type 1 Diabetes Mellitus Using Interleukin-27.

Authors:  Fatemeh Zamani; Shohreh Almasi; Tohid Kazemi; Rana Jahanban Esfahlan; Mohammad Reza Aliparasti
Journal:  Adv Pharm Bull       Date:  2015-12-31

6.  Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery.

Authors:  Jason Park; Wenda Gao; Roy Whiston; Terry B Strom; Su Metcalfe; Tarek M Fahmy
Journal:  Mol Pharm       Date:  2010-12-08       Impact factor: 4.939

7.  Creating transplant tolerance by taming adverse intragraft innate immunity.

Authors:  Dusan Hanidziar; Maria Koulmanda; Terry B Strom
Journal:  F1000 Biol Rep       Date:  2010-11-24

Review 8.  Multiple Sclerosis and the LIF/IL-6 Axis: Use of Nanotechnology to Harness the Tolerogenic and Reparative Properties of LIF.

Authors:  Su M Metcalfe; Terry B Strom; Anna Williams; Tarek M Fahmy
Journal:  Nanobiomedicine (Rij)       Date:  2015-01-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.